Epstein File EFTA02714314: Treat and Program for Evolutionary Dynamics (DS11)

Epstein Index›Documents›EFTA02714314

💨IMPACT LEVEL 1 — MEH

Epstein File EFTA02714314: Treat and Program for Evolutionary Dynamics (DS11)

General DocumentDate unavailableEFTA027143141 keyword hits

0

views

0

shares

0

reactions

0

persons

4

keywords

2

excerpts

A document discussing FDA approval in July 2014 of combined inhibitors idelalisib and rituximab for treating relapsed chronic lymphocytic leukemia, and referencing a pivotal study from Harvard University's Program for Evolutionary Dynamics regarding resistant cancer cells. The document combines medical regulatory information with academic research findings.

👤 Named in This Document

No named persons linked yet

🔑 Evidence Keywords

treat Program for Evolutionary Dynamics Harvard Harvard University

📋 Key Excerpts2

PersonKeyword

Excerpt 1

In July 2014, the FDA approved combined inhibitors idelaisib and rituximab to **treat** relapsed chronic lymphocytic leukemia.

Excerpt 2

A few years ago, the **Program** **for** **Evolutionary** **Dynamics** at Harvard University came out with a pivotal study showing that one resistant cell out of a million